bioRxivCancer BiologyPreprint
The oncogenic Runx3-Myc axis defines p53-deficient osteosarcomagenesis
S. Otani, Y. Date, T. Ueno, T. Ito, S. Kajikawa, K. Omori, I. Taniuchi, M. Umeda, T. Komori, J. Toguchida, K. Ito
Abstract
Osteosarcoma (OS) in human patients is characterized by genetic alteration of TP53. Osteoprogenitor-specific p53-deleted mice (OS mice) have been widely used to study the process of osteosarcomagenesis. However, the molecular mechanisms responsible for the development of OS upon p53 inactivation remain largely unknown. In this study, we detected prominent RUNX3/Runx3 expression in human and mouse p53-deficient OS. Myc was aberrantly upregulated by Runx3 via mR1, a consensus Runx site in the Myc promoter, in a manner dependent on p53 deficiency. Reduction of the Myc level by disruption of mR1 or Runx3 knockdown decreased the tumorigenicity of p53-deficient OS cells and effectively suppressed OS development in OS mice. Furthermore, Runx inhibitors exerted therapeutic effects on OS mice. Together, these results show that p53 deficiency promotes osteosarcomagenesis in human and mouse by allowing Runx3 to induce oncogenic Myc expression.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: gene regulatory network inference
- approach: experimental assay
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- WWOX promotes osteosarcoma development via upregulation of Myc
R. Akkawi, O. Hidmi, … R. I. Aqeilan·bioRxiv·Mar 14, 2023
- Oncogenic role of sFRP2 in P53-mutant osteosarcoma development via autocrine and paracrine mechanism
H. S. Kim, S. Yoo, … C. Schaniel·bioRxiv·Jan 10, 2018
- Myogenic and neural transcriptional circuitry determines PAX3::FOXO1 driven initiation of rhabdomyosarcoma
Bradley T. Stevens, Yang Zhang, … Mark E. Hatley·bioRxiv·Oct 29, 2026
- Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma
Tomoya Ueno, Shohei Otani, … Kosei Ito·Cancer SciencePeer-reviewed·Jun 26, 2024
- Targeted inhibition of SCF-SKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma
J. Wang, A. Ferrena, … B. H. Hoang·bioRxiv·May 13, 2023
- miRNA-34c suppresses osteosarcoma progression in vivo by targeting Notch and E2F
Y. Bae, H.-C. Zeng, … B. H. Lee·bioRxiv·May 24, 2021